Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先 健 科 技 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE

This is a voluntary announcement made by LifeTech Scientific Corporation (the "Company").

The board (the "**Board**") of directors (the "**Directors**") of the Company hereby announces that it has exercised and intends to further exercise its powers under the repurchase mandate (the "**Repurchase Mandate**") granted by the shareholders of the Company (the "**Shareholders**") to the Board at the annual general meeting (the "**AGM**") of the Company held on 25 May 2018 to repurchase shares of the Company (the "**Shares**") (the "**Share Repurchase**"). Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 433,629,000 Shares, being 10% of the total issued Shares as at the date of the AGM, on The Stock Exchange of Hong Kong Limited.

The Board believes that the Shares have been trading at a price which undervalues the Company's intrinsic value. The Share Repurchase reflects the confidence of the Board and the management team in the long-term strategy, growth and prospects of the Company. The Board believes that the current financial resources of the Company enables it to conduct the Repurchase while maintaining a solid financial position for the continuation of the Company's business.

On 10 December 2018, the Company repurchased 640,000 Shares on the Stock Exchange at the average price of HK\$1.4963 per Share, representing approximately 0.0148% of the issued share capital of the Company immediately prior to the Share Repurchase. The total amount paid was approximately HK\$957,600. The Shares repurchased by the Company will subsequently be cancelled.

Shareholders and potential investors should note that further Share Repurchase under the Repurchase Mandate will be subject to market conditions and at the sole discretion of the Board. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

> By order of the Board LifeTech Scientific Corporation XIE Yuehui Chairman, Chief Executive Officer and Executive Director

Hong Kong, 10 December 2018

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. ZHANG Deyuan and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.